PR Newswire Clinical TrialsOriginal article
19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD
Data ReadoutpositiveOlatorepatidePositive
AI Analysis
Summary
Hansoh Pharma presented Phase 3 data for Olatorepatide, its dual-biased GLP-1/GIP agonist, showing 19.3% weight loss at week 48 in patients, presented at the EASD Annual Meeting in Milan.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
19.3% weight loss at week 48 in Phase III trial
Importance:7/10
Sentiment:
0.70
Phase 3 dataGLP-1/GIP agonistweight lossEASD conferencedual-biased
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 4:00 AM